Cancer Discovery

Article	Citations
Hallmarks of Cancer: New Dimensions	3245
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak	1143
Therapeutic Targeting of the Tumor Microenvironment	650
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System	589
Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer	418
Liquid Biopsy: From Discovery to Clinical Application	401
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors	382
The Next Decade of Immune Checkpoint Therapy	365
Tuning the Antigen Density Requirement for CAR T-cell Activity	294
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?	292
Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level	283
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia	243
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation	237
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer	234
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab	223
Tumor-Infiltrating Natural Killer Cells	222
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition	214
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells	212
Artificial Intelligence in Cancer Research and Precision Medicine	209
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges	203
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors	199
Paradigms on Immunotherapy Combinations with Chemotherapy	194
Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment	192
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers	188
Diffuse Glioma Heterogeneity and Its Therapeutic Implications	188

Modes of Regulated Cell Death in Cancer	186
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction	184
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer	172
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade	167
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer	165
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy	162
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited	158
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)	151
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes	151
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial	149
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC	147
Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation	145
HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers	144
Lower Airway Dysbiosis Affects Lung Cancer Progression	144
Metabolic Codependencies in the Tumor Microenvironment	144
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition	143
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib	142
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors	141
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention	140
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer	137
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer	136
Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner	136
Metastasis-Initiating Cells and Ecosystems	135
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence	133
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma	132
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy	132
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis	132
Development of Immunotherapy Combination Strategies in Cancer	132
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer	128
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer	127
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response	127
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers	124
Targeting the p300/CBP Axis in Lethal Prostate Cancer	123
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer	121
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures	120
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study	118
Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment	118
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype	118
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease	117
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma	117
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis	116
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets	110
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies	109
WNT as a Driver and Dependency in Cancer	109
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem	109
Mobocertinib (TAK-788): A Targeted Inhibitor ofEGFRExon 20 Insertion Mutants in Non–Small Cell Lung Cancer	108
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants	107
Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer	105
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade	104
Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma	102

Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer	102
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study	99
Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas	99
Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer	98
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance	97
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade	96
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer	96
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy	94
Independent Drug Action in Combination Therapy: Implications for Precision Oncology	94
Synthetic Lethality in Cancer Therapeutics: The Next Generation	93
Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer–Associated Fibroblasts	93
Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast–Driven Nutritional Support and Immunosuppression	92
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers	92
TargetingMETDysregulation in Cancer	92
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy	91
Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic	91
Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes	90
A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes	89
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy	89
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab	89
Advances in Targeting RET-Dependent Cancers	88
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition	88
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy	88
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing	88
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer	87
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota	86
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer	85
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells	84
IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity	84
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity	84
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia	83
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia	83
The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution	83
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy	83
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?	82
Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity	81
Epigenetic Switch–Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer	81
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma	79
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome	78
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial	78
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers	78
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative	77
Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2	76
CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies	75
Direct and Indirect Regulators of Epithelial–Mesenchymal Transition–Mediated Immunosuppression in Breast Carcinomas	74
Tracking Cancer Evolution through the Disease Course	74
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders	74
A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation	73
Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs	73
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution	73
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia	72
Tumor Immunity and Immunotherapy for HPV-Related Cancers	71
Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization	70
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer	70
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade	70
Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors	69
A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era	69
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors	69
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants	69
The Evolutionary Origins of Recurrent Pancreatic Cancer	69
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies	68
Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis	67
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis	67
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer	67
IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment	67
Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity	67
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing	67
NRF2: KEAPing Tumors Protected	66
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety	66
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression	66
Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations	66
Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation	65
The Complex Integration of T-cell Metabolism and Immunotherapy	65
Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers	65
Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin	65
Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site	65
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma	65
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade	64
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy	64
Redox Regulation in Cancer Cells during Metastasis	63

Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies	62
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory	61
Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation	60
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements	59
Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer	59
Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System	59
Mechanisms of Resistance to KRASG12C-Targeted Therapy	58
Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation	58
Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer	58
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC	57
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo	57
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer	56
Cell of Origin Influences Pancreatic Cancer Subtype	56
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies	55
DietaryLactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy	55
Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression	54
Next-Generation CAR T-cell Therapies	54
Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches	54
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity	54
Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer	53
Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy	52
Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma	52
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly EffectiveIn Vivowithout Systemic Immune Activation	51
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C	51
TargetingEGFRExon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates	51
Lineage Reversion Drives WNT Independence in Intestinal Cancer	51
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer	50
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma	50
Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung	49
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease	49
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients	49
Combined Cohesin–RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes	49
Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness	49
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor	48
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy	47
DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells	47
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade	47
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions	46
ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma	46
Cancer in the Fourth Dimension: What Is the Impact of Circadian Disruption?	45
Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing	45
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity	45
African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent	45
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity	45
FGFR2Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma	45
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN	45
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain	44
Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma	44
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown	44
Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance	44
The Cancer Microbiome: Recent Highlights and Knowledge Gaps	43
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages	43
MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression	43
The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2	43
Bacterial-Driven Inflammation and Mutant BRAF Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy	42
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer	42
NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron–Sulfur Cluster Proteins	42
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells	42
Discovery and Features of an Alkylating Signature in Colorectal Cancer	42
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis	42
Sex-BiasedZRSR2Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis	41
Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis	41
Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer	41
H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone	41
Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia	41
Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation	41
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors	41
Discovery of Candidate DNA Methylation Cancer Driver Genes	40
Human Colon Cancer–Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice	40
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease	40
Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells	39
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer	39
Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes	39
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis	39
Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti–PD-1 Treatment	39
Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia	38
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death	38
Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL	38
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy	38
Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma	37
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia	37
Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy	37
Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas	37
Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy	37
Decoding Cancer Biology One Cell at a Time	36
A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung Cancer	36
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade	36
Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry	36
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis	36
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant inPIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers	36
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors	36
Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1	36
Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis	35
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth	35
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer	35